[Passants devant les pylônes dédiés à la bataille de l'Argonne, allégorie de la victoire, autour du 13 juillet 1919, aux environs des Champs-Elysées] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54848

[Foule importante au rond-point des Champs-Elysées, pylônes dédiés à la bataille du Grand Couronné, allégorie de la victoire, pyramide de canons pris à l'ennemi, autel de la cité martyre Verdun, autour du 13 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54844

[Arc de triomphe de l'Etoile, le cénotaphe, foule importante, 13 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54888

[Le cénotaphe sous l'Arc de triomphe de l'Etoile, le 13 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54882

13-7-19, le cénotaphe, arc de triomphe [place de l'Etoile, foule nombreuse] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54866

13-7-19, le cénotaphe, place de l'Etoile : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54865

13-7-19, Arc de triomphe de l'Etoile [édification du cénotaphe, foule importante] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54859

[Passants près des pylônes dédiés à la bataille d'Alsace, allégorie de la victoire, autour du 13 juillet 1919, quartier des Champs-Elysées] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54857

[Foule importante au rond-point des Champs-Elysées, pylônes dédiés aux batailles d'Alsace, de l'Ourcq et de la Marne, allégorie de la victoire, pyramide de canons pris à l'ennemi, autel de la cité martyre d'Arras, autour du 13 juillet 1919] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54856

Lottery Action, December 13, 2004 - January 2, 2005, Vol. 11, no. 23

Iowa Lottery Newsletter for Retailers

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Background Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on the efficacy of cetuximab in, to our knowledge, the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era. Methods 1022 tumour DNA samples (73 from fresh-frozen and 949 from formalin-fixed, paraffin-embedded tissue) from patients treated with cetuximab between 2001 and 2008 were gathered from 11 centres in seven European countries. 773 primary tumour samples had sufficient quality DNA and were included in mutation frequency analyses; mass spectrometry genotyping of tumour samples for KRAS, BRAF, NRAS, and PIK3CA was done centrally. We analysed objective response, progression-free survival (PFS), and overall survival in molecularly defined subgroups of the 649 chemotherapy-refractory patients treated with cetuximab plus chemotherapy. Findings 40.0% (299/747) of the tumours harboured a KRAS mutation, 14.5% (108/743) harboured a PIK3CA mutation (of which 68.5% [74/108] were located in exon 9 and 20.4% [22/108] in exon 20), 4.7% (36/761) harboured a BRAF mutation, and 2.6% (17/644) harboured an NRAS mutation. KRAS mutants did not derive benefit compared with wild types, with a response rate of 6.7% (17/253) versus 35.8% (126/352; odds ratio [OR] 0.13, 95% CI 0.07-0.22; p<0.0001), a median PFS of 12. weeks versus 24 weeks (hazard ratio [HR] 1 98, 1.66-2.36; p<0.0001), and a median overall survival of 32 weeks versus 50 weeks (1.75, 1.47-2.09; p<0.0001). In KRAS wild types, carriers of BRAF and NRAS mutations had a significantly lower response rate than did BRAF and NRAS wild types, with a response rate of 8.3% (2/24) in carriers of BRAF mutations versus 38.0% in BRAF wild types (124/326; OR 0.15, 95% CI 0.02-0.51; p=0.0012); and 7.7% (1/13) in carriers of NRAS mutations versus 38.1% in NRAS wild types (110/289; OR 0.14, 0.007-0.70; p=0.013). PIK3CA exon 9 mutations had no effect, whereas exon 20 mutations were associated with a worse outcome compared with wild types, with a response rate of 0.0% (0/9) versus 36.8% (121/329; OR 0.00,0.00-0.89; p=0.029), a median PFS of 11.5 weeks versus 24 weeks (HR 2.52, 1.33-4.78; p=0.013), and a median overall survival of 34 weeks versus 51 weeks (3.29, 1.60-6.74; p=0.0057). Multivariate analysis and conditional inference trees confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA exon 20 mutations (in that order) gives additional information about outcome. Objective response rates in our series were 24.4% in the unselected population, 36.3% in the KRAS wild-type selected population, and 41.2% in the KRAS, BRAF, NRAS, and PIK3CA exon 20 wild-type population. Interpretation While confirming the negative effect of KRAS mutations on outcome after cetuximab, we show that BRAF, NRAS, and PIK3CA,exon 20 mutations are significantly associated with a low response rate. Objective response rates could be improved by additional genotyping of BRAF, NRAS, and PIK3CA exon 20 mutations in a KRAS wild-type population.

Kyrie eleison [VIII] : 13 °Centenaire de St. Grégoire Magno : chant grégorien d'aprés la 2e édition de Solesmes / [Dom Antonio] Rella, chef de choeur

[Chant grégorien. Messe]